[go: up one dir, main page]

KR950702419A - 오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트(injection and injection kit containing omeprazole and its analogs) - Google Patents

오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트(injection and injection kit containing omeprazole and its analogs) Download PDF

Info

Publication number
KR950702419A
KR950702419A KR1019950700327A KR19950700327A KR950702419A KR 950702419 A KR950702419 A KR 950702419A KR 1019950700327 A KR1019950700327 A KR 1019950700327A KR 19950700327 A KR19950700327 A KR 19950700327A KR 950702419 A KR950702419 A KR 950702419A
Authority
KR
South Korea
Prior art keywords
injection
salt
solvent
methylsulfinyl
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019950700327A
Other languages
English (en)
Other versions
KR100258423B1 (ko
Inventor
시게오 나까니시
데쓰오 도미나가
이와오 야마나까
다까시 히고
도시유끼 시바따
Original Assignee
클래스 빌헬름슨
아스트라 악티에볼라그
고오야 다다시
요시또미 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16437061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR950702419(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 클래스 빌헬름슨, 아스트라 악티에볼라그, 고오야 다다시, 요시또미 세이야꾸 가부시끼가이샤 filed Critical 클래스 빌헬름슨
Publication of KR950702419A publication Critical patent/KR950702419A/ko
Application granted granted Critical
Publication of KR100258423B1 publication Critical patent/KR100258423B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

본 발명은 항궤양 활성을 갖는 2-[(2-피리딜)메틸술피닐]벤즈이미다졸 화합물 또는 그의 염과 비수성 용매가 첨가되지 않은 수성 용매로 이루어지는, 9.5 내지 11.5의 pH를 갖는 주사제, 및 (a) : 항궤양 활성을 갖는 2-[(2-피리딜)메틸술피닐]벤즈이미다졸 화합물 또는 그의 염과 알칼리 수용액의 동결 건조 생성물, (b) : 비수성 용매가 첨가되지 않은 수성 용매로 이루어지고, (a)를 (b)에 용해시켰을 때의 pH가 9.5 내지 11.5가 되도록 상기 (a)와 (b)를 조정하여 만든 주사제 키트에 관한 것이다. 본 발명의 주사제는 용혈 현상 및 국소 자극을 방지하기 위하여 pH를 저하시키고 용해 특성의 부수적 열화를 방지하기 위하여 용해용 수성용매에 폴리에틸렌 글리콜과 같은 비수성 용매를 첨가할 필요가 없다. 결과적으로, 비수성 용매에 의해 비롯되는 자극 및 용혈 현상은 없앨수 있다. 따라서, 본 발명의 주사제는 배합물을 제제화하는데 충분한 용해도 및 인체를 위한 안정성을 보장할 수 있다.

Description

오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트(INJECTION AND INJECTION KIT CONTAINING OMEPRAZOLE AND ITS ANALOGS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 항궤양 활성을 갖는 2-[(2-피리딜)메틸술피닐]벤즈이미다졸 화합물 또는 그의 염과, 비수성 용매가 첨가되지 않은 수성 용매로 이루어지는 9.5 내지 11.5의 pH를 갖는 주사제.
  2. 제1항에 있어서, 항궤양 활성을 갖는 2-[(2-피리딜)메틸술피닐]벤즈이미다졸 화합물 또는 그의 염의 알칼리 수용액의 동결 건조 생성물을 비수성 용매가 첨가되지 않은 수성 용매에 용해시켜 제조한 주사제.
  3. (a) : 항궤양 활성을 갖는 2-[(2-피리딜)메틸술피닐]벤즈이미다졸 화합물 또는 그의 염의 알칼리 수용액의 동결 건조 생성물, (b) : 비수성 용매가 첨가되지 않은 수성용매로 이루어지고, (a)를 (b)에 용해시켰을 때의 pH가 9.5 내지 11.5가 되도록 상기 (a)와 (b)를 조정하여 만든 주사제 키트.
  4. 제1항 또는 제2항에 있어서, 2-[(2-피리딜)메틸술피닐]벤즈이미다졸 화합물 또는 그의 염이 오메프라졸의 나트륨 염인 주사제.
  5. 제3항에 있어서, 2-[(2-피리딜)메틸술피닐]벤즈이미다졸 화합물 또는 그의 염이 오메프라졸의 나트륨 염인 주사제 키트.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950700327A 1992-07-28 1993-07-15 오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트 Expired - Fee Related KR100258423B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP92-201203 1992-07-28
JP20120392 1992-07-28
PCT/JP1993/000998 WO1994002141A1 (en) 1992-07-28 1993-07-15 Injection and injection kit containing omeprazole and its analogs

Publications (2)

Publication Number Publication Date
KR950702419A true KR950702419A (ko) 1995-07-29
KR100258423B1 KR100258423B1 (ko) 2000-07-01

Family

ID=16437061

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950700327A Expired - Fee Related KR100258423B1 (ko) 1992-07-28 1993-07-15 오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트

Country Status (20)

Country Link
US (1) US5589491A (ko)
EP (1) EP0652751B1 (ko)
KR (1) KR100258423B1 (ko)
AT (1) ATE144421T1 (ko)
AU (1) AU674015B2 (ko)
CA (1) CA2140347C (ko)
CZ (1) CZ284249B6 (ko)
DE (1) DE69305642T2 (ko)
DK (1) DK0652751T3 (ko)
ES (1) ES2093445T3 (ko)
FI (1) FI113338B (ko)
GR (1) GR3021937T3 (ko)
HK (1) HK52397A (ko)
HU (1) HU226778B1 (ko)
NO (1) NO304098B1 (ko)
NZ (1) NZ254237A (ko)
RU (1) RU2126252C1 (ko)
SG (1) SG52479A1 (ko)
SK (1) SK279554B6 (ko)
WO (1) WO1994002141A1 (ko)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4324014C2 (de) * 1993-07-17 1995-06-08 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung einer in Wasser rekonstituierbaren Zubereitung
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
US7396841B2 (en) 2000-08-18 2008-07-08 Takeda Pharmaceutical Company Limited Injections
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
MY137726A (en) 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
KR100467100B1 (ko) * 2002-03-20 2005-01-24 일양약품주식회사 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040081671A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
ATE466579T1 (de) 2003-11-05 2010-05-15 Lyka Labs Ltd Verfahren zur herstellung von benzimidazolen
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
WO2007091276A2 (en) * 2006-02-10 2007-08-16 Rajasthan Antibiotic Limited Novel crystal form of omeprazol sodium
CN104288175A (zh) * 2014-09-17 2015-01-21 大生祥(武汉）中医投资管理有限公司 一种新的苯并咪唑类异构体制剂及其制备方法
US11318123B2 (en) * 2015-12-08 2022-05-03 Luoda Pharma Limited Methods and compositions for treating gastric ulcers
CN105919953A (zh) * 2016-06-27 2016-09-07 峨眉山通惠制药有限公司 一种注射用奥美拉唑钠组合物及其制作工艺
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
CN112807282A (zh) * 2021-01-13 2021-05-18 海南葫芦娃药业集团股份有限公司 一种奥美拉唑钠冻干粉针剂及其制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK399389A (da) * 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd Injicerbare oploesninger
ATE114114T1 (de) * 1989-02-10 1994-12-15 Takeda Chemical Industries Ltd Verwendung von benzimidazol-derivaten als antibakterielle mittel.
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles

Also Published As

Publication number Publication date
NZ254237A (en) 1995-12-21
HUT71900A (en) 1996-02-28
NO304098B1 (no) 1998-10-26
AU674015B2 (en) 1996-12-05
EP0652751A1 (en) 1995-05-17
RU2126252C1 (ru) 1999-02-20
DE69305642D1 (de) 1996-11-28
ES2093445T3 (es) 1996-12-16
CZ21795A3 (en) 1995-10-18
KR100258423B1 (ko) 2000-07-01
EP0652751B1 (en) 1996-10-23
ATE144421T1 (de) 1996-11-15
FI950379A0 (fi) 1995-01-27
HU9500245D0 (en) 1995-03-28
NO950178L (no) 1995-01-17
FI113338B (fi) 2004-04-15
CZ284249B6 (cs) 1998-10-14
HU226778B1 (en) 2009-10-28
AU4583893A (en) 1994-02-14
WO1994002141A1 (en) 1994-02-03
SG52479A1 (en) 1998-09-28
SK10095A3 (en) 1995-07-11
NO950178D0 (no) 1995-01-17
GR3021937T3 (en) 1997-03-31
SK279554B6 (sk) 1998-12-02
DE69305642T2 (de) 1997-02-27
FI950379L (fi) 1995-01-27
CA2140347A1 (en) 1994-02-03
CA2140347C (en) 2001-03-27
HK52397A (en) 1997-05-02
DK0652751T3 (da) 1996-11-18
US5589491A (en) 1996-12-31

Similar Documents

Publication Publication Date Title
KR950702419A (ko) 오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트(injection and injection kit containing omeprazole and its analogs)
RU95104936A (ru) Препарат для инъекций и набор для инъекций, содержащие омепразол и его аналоги
DK354785A (da) Stabile salte af s-adenosyl-l-methionin med polyanioner
DE69107932D1 (de) Stabile wässerige Zubereitung.
KR950703988A (ko) 긴 보장기간을 갖는 g-csf의 수성 약제 조성물(aqueous pharmaceutical preparations of g-csf whth a long shelf life)
KR940703689A (ko) 성장호르몬과 아스파라진으로 이루어지는 안정화된 약학제제(a stabil-ized pharmaceutical formulation comprising growth gormone and asparagine)
DE69112914D1 (de) Herstellungsverfahren von Mikrokugeln.
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
KR910016697A (ko) 테트라히드로피리딘 유도체
ES2111083T3 (es) Composiciones que contienen antibioticos de quinolona y poli(sulfonato de estireno).
DK0666739T3 (da) Intravenøs opløsning som formindsker protein- og vandtab fra kroppen
ATE65401T1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
KR870006892A (ko) 니코란딜 함유 주사제
JP3954115B2 (ja) 注射剤および注射剤キット
US4128632A (en) Solubilization of Rafoxanide
KR880008801A (ko) 비경구 투여용 용액제
BR9004692A (pt) Composicao trombolitica e infusao para injecao
KR960701638A (ko) 안정화된 주사제 및 주사제의 안정화법
KR890001540A (ko) 심부전증 치료제
ATE386512T1 (de) Vorgemischte amiodaron-haltige parenterale lösung und deren herstellungsverfahren
US4089949A (en) Injectable therapeutic compositions
KR900013959A (ko) γ-카르블린 또는 그들의 제약학적으로 허용 가능한 산부가염 및/또는 수화물, 및 그들로 구성되는 제약학적 조성물
JPS56139414A (en) Stabilizing method of aqueous solution
ATE223700T1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen
KR940008683A (ko) 속용해성 주사용 세프피라마이드 제제

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19950127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19960529

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19960829

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980519

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20000214

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20000310

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20000311

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20030123

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20040113

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20050114

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20060113

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20070112

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20080117

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20080117

Start annual number: 9

End annual number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20100210